[{"indications": "Indications\u00a0Parkinson\u2019s\r\ndisease, \n(From Levodopa: British National Formulary)\nLevodopa", "name": "CO-BENELDOPA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Levodopa", "CO-BENELDOPA"], "cautions": "Cautions\u00a0\n(From Levodopa: British National Formulary)\nCautions\u00a0Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing\u2019s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving); interactions: Appendix 1 (levodopa).", "side-effects": "Side-effects\u00a0\n(From Levodopa: British National Formulary)\nSide-effects\u00a0Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arrhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideation), anxiety, dizziness, dystonia, dyskinesia, and chorea.Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastro-intestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dyspnoea, agitation, paraesthesia, bruxism, trismus, hiccups, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Horner\u2019s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Sch\u00f6nlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour (see Impulse Control Disorders) and false positive tests for urinary ketones have also been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/215615.htm", "doses": ["Expressed as levodopa, initially 50\u00a0mg\r\n3\u20134 times daily (100\u00a0mg 3 times daily in advanced disease), increased\r\nby 100\u00a0mg daily once or twice weekly according to response; usual\r\nmaintenance dose 400\u2013800\u00a0mg daily in divided doses; elderly initially 50\u00a0mg once or twice daily, increased\r\nby 50\u00a0mg daily every 3\u20134 days according to response", "When transferring patients from another levodopa/dopa-decarboxylase\r\ninhibitor preparation, the previous preparation should be discontinued\r\n12 hours before (although interval can be shorter)", "When administered as an adjunct to other\r\nantiparkinsonian drugs, once therapeutic effect apparent, the other\r\ndrugs may be reduced or withdrawn", "When switching from modified-release levodopa\r\nto dispersible co-beneldopa, reduce dose by approx. 30%"], "pregnancy": "Pregnancy\u00a0\n(From Levodopa: British National Formulary)\nPregnancy\u00a0Levodopa should be used with caution in pregnancy\u2014toxicity has occurred in animal studies.Breast-feeding\u00a0Levodopa may suppress lactation. It is present in milk\u2014avoid."}, {"indications": "Indications\u00a0Parkinson\u2019s\r\ndisease, \n(From Levodopa: British National Formulary)\nLevodopa", "name": "CO-BENELDOPA Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Levodopa", "CO-BENELDOPA", "Modified release"], "cautions": "Cautions\u00a0\n(From Levodopa: British National Formulary)\nCautions\u00a0Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing\u2019s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving); interactions: Appendix 1 (levodopa).", "side-effects": "Side-effects\u00a0\n(From Levodopa: British National Formulary)\nSide-effects\u00a0Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arrhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideation), anxiety, dizziness, dystonia, dyskinesia, and chorea.Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastro-intestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dyspnoea, agitation, paraesthesia, bruxism, trismus, hiccups, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Horner\u2019s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Sch\u00f6nlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour (see Impulse Control Disorders) and false positive tests for urinary ketones have also been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3638.htm", "doses": ["Expressed as levodopa, initially 50\u00a0mg\r\n3\u20134 times daily (100\u00a0mg 3 times daily in advanced disease), increased\r\nby 100\u00a0mg daily once or twice weekly according to response; usual\r\nmaintenance dose 400\u2013800\u00a0mg daily in divided doses; elderly initially 50\u00a0mg once or twice daily, increased\r\nby 50\u00a0mg daily every 3\u20134 days according to response", "When transferring patients from another levodopa/dopa-decarboxylase\r\ninhibitor preparation, the previous preparation should be discontinued\r\n12 hours before (although interval can be shorter)", "When administered as an adjunct to other\r\nantiparkinsonian drugs, once therapeutic effect apparent, the other\r\ndrugs may be reduced or withdrawn", "When switching from modified-release levodopa\r\nto dispersible co-beneldopa, reduce dose by approx. 30%", "Patients transferring from immediate-release levodopa/dopa-decarboxylase\r\ninhibitor preparations, initially 1 capsule substituted for every\r\n100\u00a0mg of levodopa and given at same dosage frequency,\r\nincreased every 2\u20133 days according to response; average increase of\r\n50% needed over previous levodopa dose and titration\r\nmay take up to 4 weeksSupplementary dose of immediate-release Madopar\u00ae may be needed with first morning dose; if response\r\nstill poor to total daily dose of Madopar\u00ae CR plus Madopar\u00ae corresponding to 1.2\u00a0g levodopa, consider alternative therapy", "Name[Madopar\u00ae CR (Roche) ] Capsules, m/r, dark green/light\r\nblue, co-beneldopa 25/100 (benserazide 25\u00a0mg (as\r\nhydrochloride), levodopa 100\u00a0mg), net price 100-cap\r\npack = \u00a312.77. \r\n    Label:\r\n    5, 10, 14, 25, counselling, driving, see notes aboveDose\u00a0patients not taking levodopa/dopa-decarboxylase inhibitor\r\ntherapy, initially 1 capsule 3 times daily (max. initial dose 6 capsules\r\ndaily)Patients transferring from immediate-release levodopa/dopa-decarboxylase\r\ninhibitor preparations, initially 1 capsule substituted for every\r\n100\u00a0mg of levodopa and given at same dosage frequency,\r\nincreased every 2\u20133 days according to response; average increase of\r\n50% needed over previous levodopa dose and titration\r\nmay take up to 4 weeksSupplementary dose of immediate-release Madopar\u00ae may be needed with first morning dose; if response\r\nstill poor to total daily dose of Madopar\u00ae CR plus Madopar\u00ae corresponding to 1.2\u00a0g levodopa, consider alternative therapy"], "pregnancy": "Pregnancy\u00a0\n(From Levodopa: British National Formulary)\nPregnancy\u00a0Levodopa should be used with caution in pregnancy\u2014toxicity has occurred in animal studies.Breast-feeding\u00a0Levodopa may suppress lactation. It is present in milk\u2014avoid."}]